Ovid Therapeutics (OVID) AI Stock Analysis

• Market Cap: $345.51M
• Dividend Yield: N/A
• Average Volume (3M): 2.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: 946.61%
• EPS Growth: -11.30%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 131,874,630
• 10 Day Avg. Volume: 6,548,839
• 30 Day Avg. Volume: 2,936,851
• PEG Ratio: 0.20
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 16.57
• P/FCF Ratio: -3.14
• Enterprise Value/Market Cap: 0.54
• Enterprise Value/Revenue: 25.76
• Enterprise Value/Gross Profit: 25.98
• Enterprise Value/Ebitda: -4.47
• 1Y Price Target: $4.22
• Price Target Upside: 61.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -0.45
• Revenue Forecast (FY): $166.86K

• Rating: 58 Neutral
• Price Target: $2.50 ▼(-4.58% Downside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

Overall score reflects a strong capital structure and positive financing/clinical progress, partially offset by ongoing losses and negative free cash flow. Technicals are supportive but appear overextended, and valuation is constrained by negative earnings and no dividend.

Positive Factors

Conservative leverage (very low debt)

Near-zero debt gives Ovid durable financial flexibility: it reduces solvency risk, preserves capacity to fund R&D without immediate refinancing, and strengthens negotiating leverage with partners. A conservative capital structure supports sustaining clinical programs over the next 2–6 months.

$60M PIPE extends development runway

The $60M private placement materially reduces near-term financing risk and underwrites planned OV329 and OV4071 studies. Having committed financing that management expects to extend funding into late 2028 increases the likelihood of achieving upcoming clinical milestones without immediately dilutive financing.

Positive Phase 1 OV329 safety data and program expansion

Favorable Phase 1 safety supports dose selection and de-risks near-term patient studies. Expanding OV329 into pediatric epilepsies and initiating a pediatric formulation can broaden addressable markets and enable accelerated regulatory pathways, strengthening long-term commercial potential.

Negative Factors

Negative operating and free cash flow

Sustained negative operating and free cash flow means Ovid will remain dependent on external financing to fund trials. Continued cash burn increases dilution risk, constrains optionality for parallel studies, and could force prioritization or delays if future financing terms deteriorate.

Ongoing net losses and deeply negative margins

Persistent losses and negative margins indicate the business has yet to scale toward sustainable profitability. Earnings sensitivity to irregular revenue streams and continued R&D spend means profitability remains uncertain over the medium term absent successful product commercialization or large milestone receipts.

No commercial products; revenue is partnership-dependent

Lack of commercialized products makes revenue lumpy and contingent on collaborations, milestones, and future approvals. This structural dependency raises execution risk: setbacks in trials or partner negotiations can sharply reduce cash inflows and delay a transition to recurring product revenue.

Ovid Therapeutics Business Overview & Revenue Model

Company Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

How the Company Makes Money

Ovid Therapeutics’ revenue model is typical of a clinical-stage biotechnology company: it may generate income primarily from (a) collaboration and licensing arrangements (such as upfront payments, reimbursement for research and development services, milestone payments tied to development/regulatory/commercial events, and royalties on future sales if partnered products are commercialized), and (b) other operating income associated with such agreements. If Ovid has no currently commercialized product, it generally would not have meaningful recurring product sales revenue, and its ability to generate substantial cash inflows depends on executing partnerships, achieving development milestones that trigger payments, and/or eventually obtaining regulatory approvals and commercializing products (directly or via partners). Specific details on current product-sales revenue, named material partnerships, and the exact composition of recent-period revenues are null.

Ovid Therapeutics Financial Statement Overview

Summary

Mixed fundamentals: a strong, low-debt balance sheet (debt-to-equity ~0.01) offsets weak and volatile operating results. The company remains unprofitable with continued cash burn in 2025, though losses and cash outflows improved versus prior years and revenue rebounded in 2025.

Income Statement

Revenue is highly volatile: a large revenue base in 2021 was followed by a collapse in 2022–2024, with a rebound in 2025 (annual revenue up ~9.7%). Profitability is currently weak, with sizable operating losses and a net loss in 2025, after multiple loss years; margins have been deeply negative in 2022–2024 and remain negative in 2025. The main positive is that losses have narrowed versus 2023–2024, but the overall earnings profile is still inconsistent and dependent on non-recurring or uneven revenue sources.

Balance Sheet

Leverage looks conservative: total debt is very low relative to equity in 2025 (debt-to-equity ~0.01), improving materially from 2022–2024 levels. Equity remains sizable, supporting the balance sheet, though returns on equity are negative in recent years due to ongoing net losses. Overall, the capital structure is a strength, while persistent losses remain the key risk to balance-sheet durability over time.

Cash Flow

Cash generation is currently negative, with operating cash flow and free cash flow both meaningfully negative in 2025. Cash burn improved versus 2024 (operating cash flow less negative), but free cash flow growth is only marginally positive, indicating continued funding needs. A positive offset is that free cash flow broadly tracks reported earnings (free cash flow roughly in line with net income in recent years), but the absolute level of cash outflow remains the dominant concern.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.25M	566.00K	392.00K	1.50M	208.38M
Gross Profit	6.95M	566.00K	392.00K	1.50M	208.38M
EBITDA	-42.44M	-57.77M	-57.01M	-54.17M	124.45M
Net Income	-17.41M	-26.43M	-52.34M	-54.17M	122.83M
Balance Sheet
Total Assets	150.93M	92.17M	144.03M	155.27M	194.54M
Cash, Cash Equivalents and Short-Term Investments	90.45M	53.08M	105.83M	129.00M	187.80M
Total Debt	1.43M	14.76M	16.00M	16.54M	0.00
Total Liabilities	20.27M	23.94M	56.23M	22.99M	14.80M
Stockholders Equity	130.66M	68.23M	87.80M	132.27M	179.75M
Cash Flow
Free Cash Flow	-38.33M	-56.03M	-45.92M	-56.65M	118.43M
Operating Cash Flow	-38.33M	-55.96M	-45.78M	-55.23M	118.61M
Investing Cash Flow	-49.85M	54.59M	-2.58M	-87.88M	-1.82M
Financing Cash Flow	75.21M	622.00K	30.54M	180.66K	904.08K

Ovid Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OVID, the sentiment is Positive. The current price of 2.62 is above the 20-day moving average (MA) of 1.91, above the 50-day MA of 1.71, and above the 200-day MA of 1.26, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 80.28 is Negative, neither overbought nor oversold. The STOCH value of 76.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OVID.

Ovid Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	58 Neutral	$345.51M	-6.90	-23.98%	―	946.61%	-11.30%
IRD	54 Neutral	$312.34M	―	-452.26%	―	74.60%	-58.14%
IKT	54 Neutral	$218.28M	-3.06	-131.71%	―	-100.00%	79.01%
ZNTL	53 Neutral	$189.30M	-1.02	-51.49%	―	-33.76%	17.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRZN	50 Neutral	$215.57M	-0.39	―	―	-63.96%	-28.50%
BMEA	50 Neutral	$80.60M	-1.25	-209.00%	―	―	40.22%

Ovid Therapeutics Corporate Events

Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline

On March 17 and 18, 2026, Ovid Therapeutics detailed a $60 million private placement and new clinical data that together underpin an expanded epilepsy pipeline. The company agreed to sell 19.2 million common shares and pre‑funded warrants for another 10.7 million shares in a PIPE financing, which is expected to close around March 19, 2026, and will fund broader development of OV329 as well as general R&D.

Ovid reported that a 7 mg cohort of OV329 in Phase 1 showed a favorable safety and tolerability profile with only mild, transient adverse events and no treatment-related serious events, supporting dose selection for upcoming patient studies in focal onset seizures. The company is also moving OV329 into additional rare pediatric epilepsies, including tuberous sclerosis complex seizures and infantile spasms, while initiating a pediatric formulation program that could support an accelerated path and enhance its positioning in severe epilepsy markets.

The company further advanced its KCC2 portfolio, securing Australian ethics and regulatory clearance to start a Phase 1 trial of OV4071 in the second quarter of 2026, initially targeting psychosis associated with Parkinson’s disease and Lewy body dementia. With $90.4 million in cash, cash equivalents and marketable securities at December 31, 2025, and potential warrant exercises, Ovid expects to fund OV329 and OV4071 studies and operations into late 2028, extending its runway as it pursues multiple near-term clinical milestones.

The most recent analyst rating on (OVID) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.